Form 4: Edwards Lifesciences Executive Exercises Stock Options and Sells Shares Under 10b5-1 Plan

Jean-Luc M. Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On March 11, 2024, Jean-Luc M. Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences Corp, exercised employee stock options to acquire 14,400 shares of common stock at a price of $36.75 per share.
• Simultaneously, Lemercier sold 14,400 shares of Edwards Lifesciences common stock at a weighted average price of $91.677 per share, with individual sales prices ranging from $91.4500 to $92.0075.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Lemercier on August 31, 2023.
• Following these transactions, Lemercier directly owns 173,583.7785 shares of Edwards Lifesciences common stock and 28,800 employee stock options.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the transactions were pre-planned and does not necessarily reflect a change in the executive's outlook on the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any inside information at the time of the trades.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.

Key Dates